Adaptate is a biotechnology company which spun-out from GammaDelta Therapeutics in 2019. Adaptate is focused on developing therapeutic antibodies to drug targets to modulate the activity of gamma delta T cells. The company has received investment from Abingworth and Takeda Pharmaceutical Company, with support from King’s College London, the Francis Crick Institute and Cancer Research Technology